Infignos Media -- buyersUSA Consulting
NOW PLAYING
15 Radio Streams
Click Here
Alice Ridge - Anniston -- Buyer's Edge Realty
Advertise Here

From Health - Biotechnology

Brought to you by Transformation Technologies

Improve your golf scores. View our free 16 minute golf course at golf.transformationsolutions.com

Bladder Control

AstraZeneca and Isis Pharmaceuticals form strategic alliance on RNA therapeutics for cancer

Tue, 11 Dec 2012 13:44:27 EST

AstraZeneca and Isis Pharmaceuticals, Inc. today announced a strategic alliance for the discovery and development of novel generation antisense therapeutics against five cancer targets, which includes a license to develop and commercialise ISIS-STAT3Rx, a drug Isis is currently evaluating in an early clinical trial in patients with advanced lymphomas. Antisense therapies target the proteins involved in disease processes by destroying the RNA that is involved in creating these proteins. The Isis discovery platform develops specific therapies that bind to messenger RNA (mRNA) and inhibit the production of disease-causing proteins.

The strategic alliance aims to apply AstraZeneca's experience in developing personalised medicines to enhance the drug discovery and development process for four research programmes in the oncology area and to aid in the development of ISIS-STAT3Rx for patient populations that could benefit the most from inhibition of STAT3, a protein that drives cancer growth. The combination of Isis' antisense technology and its new Generation 2.5 chemistry, which increases the potency of its therapeutics, provides AstraZeneca the opportunity to develop drugs that could be much more effective in cancers that are difficult to address with conventional small molecules or antibodies.

'Isis' antisense technology platform allows AstraZeneca to broaden our oncology research efforts beyond traditional drug discovery methods, while at the same time becoming more specific about how we target cancer,' said Susan Galbraith, Head of the AstraZeneca Oncology Innovative Medicines Unit. 'AstraZeneca's expertise in oncology translational science and our global capabilities in development and commercialisation of oncology products and Isis' innovative approach to discovering novel medicines reflect a common goal of bringing new medicines to cancer patients.'

B. Lynne Parshall, Chief Operating Officer and Chief Financial Officer at Isis said: 'We are excited to collaborate with AstraZeneca, a global leader in oncology, to apply our technology and drug discovery expertise to developing novel anti-cancer agents. We will benefit from AstraZeneca's extensive oncology expertise in the use of novel pre-clinical animal models to validate targets and develop predictive assays to identify which patients would benefit the most from these new targets.'

'ISIS-STAT3Rx is our first cancer drug to incorporate our new technology and we are encouraged by the early clinical data we have observed,' said Brett Monia, Ph.D., Senior Vice President, Antisense Drug Discovery at Isis. 'While STAT3 is implicated in a number of different cancers, the focus in our ongoing clinical study is to evaluate the effectiveness of our drug in haematologic malignancies, such as lymphoma. We have worked closely with AstraZeneca to design a rapid path to the market for ISIS-STAT3Rx in these patient populations. While working toward this goal, AstraZeneca's resources, expertise and development capabilities also provide us the opportunity to evaluate ISIS-STAT3Rx as a broad-based anti-tumor agent.'

Under the terms of the agreement, Isis will receive from AstraZeneca $31 million in upfront and near term payments, comprising a $25 million payment on signing followed by a $6 million payment in the second quarter of 2013 assuming the research programme is continuing. In exchange, Isis has granted AstraZeneca an exclusive license to develop and commercialise ISIS-STAT3Rx and a pre-clinical programme as well as an option to license products developed under a separate research programme. Once licensed, AstraZeneca will be responsible for all further development and commercialisation. AstraZeneca will be responsible for all development of ISIS-STAT3Rx other than the conduct of the ongoing clinical trial, which Isis will complete. Isis is eligible to receive further milestone payments subject to achieving certain predefined clinical success criteria for the ISIS-STAT3Rx programme and pre-clinical milestones for the other programmes. Isis is also eligible to receive downstream development and approval milestone payments, license fees for research programme targets as well as royalties on sales from products that are successfully commercialised.


NOTES TO EDITORS

About ISIS-STAT3Rx

ISIS-STAT3Rx is the first drug in Isis' pipeline that incorporates Isis' Generation 2.5 chemistry, which was developed to increase potency of antisense drugs thereby creating opportunities for drugs like ISIS-STAT3Rx to be more effective in addressing targets in a broader range of tissues, including tumors. ISIS-STAT3Rx is designed to inhibit the production of signal transducer and activator of transcription 3 (STAT3), a protein critical for tumor growth and survival. Because STAT3 is overexpressed in numerous types of cancers, ISIS-STAT3Rx has the potential to be broadly useful for both solid and haematological tumors. Isis recently reported encouraging data from its ongoing Phase 1 study showing that ISIS-STAT3Rx had an acceptable safety profile and treatment with ISIS-STAT3Rx resulted in clear responses in a number of patients with advanced cancer who were refractory to multiple prior chemotherapy treatments. The indication of activity so early in development in a Phase I study prompted Isis to initiate a follow up clinical study to evaluate the safety and efficacy of ISIS-STAT3Rx in focused patient populations with lymphomas and other advanced hematologic cancers linked to activation of STAT3 who have failed other treatment options.
About Isis Pharmaceuticals, Inc.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis' partner, Genzyme, plans to commercialise Isis' lead product, KYNAMRO™, in the United States and Europe following regulatory approval. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com.

Isis Pharmaceuticals® (NASDAQ = ISIS) is a registered trademark of Isis Pharmaceuticals, Inc. KYNAMRO™ is a trademark of Genzyme Corporation.
About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.


Source: WebWire



From Our Blogs

Three Simple Ways to Trim Monthly Expenses

You can devote more toward the things you want, as well as save more for the future.

Time and Money-Saving Holiday Gift Ideas

The savings experts at Dollar General have a few gift ideas that are easy and fun to get you in the

Delight the Five Senses this Holiday Season

Turn your gifts, celebrations and home décor into a festive feast for the five senses.

Super Simple Tips to Manage and Help Prevent Diabetes

It’s no surprise that diabetes is a leading cause of death in the United States.


Sign up for our weekly newsletter.

Our Website Sponsors

Frontera Bar & Grill

Mexican quisine at it's finest. For lunch, dinner or take out, visit Frontera Bar & Grill 1750 Hamric Dr E Oxford, AL 36203? (256) 835-9905

Signature In Home Care

Our mission is to help seniors remain independent in their homes as long as possible by offering quality, affordable care. We can also provide a helping hand with activities of daily living. Call 1-877-777-1822 or 256-831-3250

Miller Funeral Home and Crematory

For pre-planning or immediate funeral services call us at 256-831-4611 or visit www.millerfuneralhomeoxford.com.

Lake Winnepesaukah Amusement Park

Come On Get Happy! The South's Favorite Family Amusement Park! 1730 Lakeview Drive, Rossville, Ga. 30741 1-877-525-3946 www.lakewinnie.com

East Alabama Regional Planning Commission

Quintard Tower, Suite 300 1130 Quintard Avenue,Anniston, AL 36201 Phone Toll Free - 800-239-6741,Local - 256-237-6741,Fax - 256-237-6763